Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer

Jian-Jian Yin1, Yan-Liang Song2, Yu-Feng Guo3

  • 1Department of Pharmacology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Frontiers in Genetics
|March 14, 2024
PubMed

Insights

This study reveals N1-methyladenosine (m1A) RNA modifications are key in bladder cancer (BLCA). Targeting TRMT61A impacts m1A patterns, affecting cancer progression and patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Post-transcriptional RNA modifications are critical in cancer development.
  • N1-methyladenosine (m1A) is an important RNA modification, but its role in bladder cancer (BLCA) is not well understood.
  • Investigating m1A in messenger RNAs (mRNAs) and long noncoding RNAs (lncRNAs) in BLCA is crucial.

Purpose of the Study:

  • To investigate the role of m1A modifications in mRNAs and lncRNAs in bladder cancer.
  • To identify the impact of TRMT61A knockdown on m1A profiles in BLCA.
  • To explore the functional implications of m1A-regulated transcripts in BLCA tumorigenesis.

Main Methods:

  • Methylated RNA immunoprecipitation sequencing (meRIP-seq) and RNA sequencing (RNA-seq) were employed.
  • TRMT61A was stably knocked down in BLCA cells to assess its effect on m1A.
  • Bioinformatic analyses including Gene Ontology and KEGG pathway analyses were performed.

Main Results:

  • Significant alterations in mRNA and lncRNA m6A methylation were observed after TRMT61A knockdown.
  • m1A-regulated transcripts are involved in protein binding and cancer signaling pathways.
  • Specific m1A-modified transcripts (SCN2B, ENST00000536140) were highly expressed in BLCA and linked to poorer patient survival.

Conclusions:

  • TRMT61A knockdown significantly alters m1A landscapes in BLCA.
  • m1A modification of mRNAs and lncRNAs plays a substantial role in BLCA progression.
  • This study provides insights into epitranscriptomic regulation in bladder cancer.